Model portefeuille
Rendement portefeulle
+12.035 %

Rendement AEX
+33.325 %

Startdatum
01-01-2009

Startwaarde portefeuille € 74082.37

Startwaarde AEX
€ 245.94


Laatste update:
29-01-2010

Esperite (ESP) - Esperite confirms the positive development of its current and future genetic activities and announces its intentions to claim 5.2 Mil

Alleen voor leden beschikbaar, wordt daarom gratis lid!

Algemeen advies 15/05/2017 07:59
Premaitha's latest action against Genoma demonstrates its desperate attempt to conceal Premaitha's financial situation. The effect of their legal action against Genoma already gives rise to negative publicity, while the legal decision in itself will hardly interrupt Genoma's business.

Genoma represented 65% of Premaitha's business in 2015/16, when Premaitha reached 2.45 Million GBP of revenues and 12 Million GBP of losses.

Genoma was forced to discontinue using the Premaitha Iona test some weeks after the serious legal claim against Premaitha's technology by Illumina (Patent Infringement).

Premaitha has not been able to demonstrate that the Iona test doesn't infringe Illumina's patents.

After Esperite acquired InKaryo in early 2015, the Group has developed its proprietary technology for genetic diagnostic tests which showed superiority and were successfully implemented.

Esperite will continue all its activities and will vigorously fight Premaitha.

Visit the websites at www.esperite.com and www.genoma.com

bericht om 10.19
Esperite (ESP) - Esperite confirms the positive development of its current and future genetic activities and announces its intentions to claim 5.2 Million euro damages against Premaitha (NIPT)

Zutphen, The Netherlands, 15 May 2017
Premaitha's latest action against Genoma demonstrates its desperate attempt to conceal Premaitha's financial situation. The effect of their legal action against Genoma already gives rise to negative publicity, while the legal decision in itself will hardly interrupt Genoma's business.

Genoma represented 65% of Premaitha's business in 2015/16, when Premaitha reached 2.45 Million GBP of revenues and 12 Million GBP of losses.

Genoma was forced to discontinue using the Premaitha Iona test some weeks after the serious legal claim against Premaitha's technology by Illumina (Patent Infringement).

Premaitha has not been able to demonstrate that the Iona test doesn't infringe Illumina's patents.

After Esperite acquired InKaryo in early 2015, the Group has developed its proprietary technology for genetic diagnostic tests which showed superiority and were successfully implemented.

Esperite will continue all its activities and will vigorously fight Premaitha.




Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord


Copyrights © 2000 by XEA.nl all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.


Copyrights © DEBELEGGERSADVISEUR.NL